comparemela.com

Latest Breaking News On - Spondyloarthritis international society - Page 6 : comparemela.com

Bimekizumab Tames Active Ankylosing Spondylitis in BE MOBILE 2

Bimekizumab Tames Active Ankylosing Spondylitis in BE MOBILE 2
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUniversity hospitalEuropean alliance of associationsLeiden university medical centerEuropean unionAssessment of spondyloarthritis international societyAnkylosing spondylitis disease activity scoreEuropean allianceSpondyloarthritis international societyMedscape medical newsAnkylosing spondylitisAnkylosing spondylitis bechterews diseaseClinical researchClinical trialsLinical studies

European AxSpA Guidelines Reflect Recent Changes in Drug Therapy

Recommendations for the management of patients with axial spondyloarthritis (axSpA) emphasize both pharmacologic and nonpharmacologic therapies.

United statesSan franciscoLianne genslerEli lillyUniversity of californiaAmerican college of rheumatologyAssessment of spondyloarthritis international societyEuropean alliance of associationsLeiden university medical centerSofia ramiroEuropean allianceSpondyloarthritis international societyCloser lookNew recommendationsMedscape medicalMerck sharp

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesBruxelles capitaleEmmanuel caeymaexEimear obrienAntje witteImmunology solutionsEuropean congressBrand communicationsUcb incDrug administrationAssessment of spondyloarthritis international societyCorporate communicationsSource ucb incExecutive vice presidentSpondyloarthritis international societyEuronext brussels

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

/PRNewswire/ UCB, a global pharmaceutical company, today announced new 24-week data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, evaluating.

United statesUnited kingdomBruxelles capitaleEmmanuel caeymaexMusculoskelet disordEimear obrienAntje witteJ clin pharmacolImmunology solutionsEuropean congressBrand communicationsUcb incDrug administrationAssessment of spondyloarthritis international societyCorporate communicationsSource ucb inc

Upadacitinib Earns FDA Approval for Ankylosing Spondylitis

Janus kinase inhibitor offers oral option for patients who have failed treatment.

Assessment in spondyloarthritis international societyEuropean medicines agencyDrug administrationSpondyloarthritis international societyAnkylosing spondylitisUs food and drug administrationNited states food and drug administrationAnkylosing spondylitis bechterews diseaseRheumatoid arthritisUlcerative colitisBiologic therapyPsoriatic arthritisClinical researchClinical trialsLinical studiesHealthcare and medical technology

vimarsana © 2020. All Rights Reserved.